Transgene (TNG) Panoramica del titolo
Transgene SA, società di biotecnologie, progetta e sviluppa in Francia vaccini terapeutici e virus oncolitici per il trattamento del cancro. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
TNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Transgene SA
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €0.83 |
| Massimo di 52 settimane | €1.50 |
| Minimo di 52 settimane | €0.64 |
| Beta | 0.73 |
| Variazione di 1 mese | 10.04% |
| Variazione a 3 mesi | -7.44% |
| Variazione di 1 anno | 26.21% |
| Variazione a 3 anni | -54.23% |
| Variazione a 5 anni | -71.52% |
| Variazione dall'IPO | -98.15% |
Notizie e aggiornamenti recenti
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.Recent updates
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...Rendimenti per gli azionisti
| TNG | FR Biotechs | FR Mercato | |
|---|---|---|---|
| 7D | -0.2% | 8.9% | 2.1% |
| 1Y | 26.2% | 339.9% | 0.8% |
Ritorno vs Industria: TNG ha avuto una performance inferiore rispetto al French Biotechs che ha registrato un rendimento 339.9 % nell'ultimo anno.
Rendimento vs Mercato: TNG ha superato il mercato French che ha restituito 0.8 % nell'ultimo anno.
Volatilità dei prezzi
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.9% |
Prezzo delle azioni stabile: TNG non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato French.
Volatilità nel tempo: La volatilità settimanale di TNG è diminuita da 10% a 4% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1979 | 145 | Alessandro Riva | www.transgene.fr |
Transgene SA, società di biotecnologie, progetta e sviluppa vaccini terapeutici e virus oncolitici per il trattamento del cancro in Francia. È impegnata nello sviluppo di TG4050, un vaccino terapeutico in fase II di sperimentazione clinica per il trattamento del cancro alle ovaie e dei tumori della testa e del collo; TG4001, un vaccino terapeutico in fase II di sperimentazione clinica per il trattamento dei tumori positivi al papillomavirus umano (HPV 16); TG6002, un virus oncolitico in fase di sperimentazione clinica I/IIa per il trattamento di tumori solidi, tra cui l'adenocarcinoma gastrointestinale; e BT-001, un virus oncolitico in fase di sperimentazione clinica I/II per il trattamento di tumori solidi. L'azienda sviluppa anche TG6050 per il trattamento del carcinoma polmonare non a piccole cellule, in fase di sperimentazione clinica di Fase 1, e Pexa-Vec, un virus oncolitico per il trattamento dei tumori solidi.
Transgene SA Riepilogo dei fondamenti
| TNG statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €228.14m |
| Utili (TTM) | -€37.52m |
| Ricavi(TTM) | €7.21m |
TNG è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| TNG Conto economico (TTM) | |
|---|---|
| Ricavi | €7.21m |
| Costo del fatturato | €33.90m |
| Profitto lordo | -€26.69m |
| Altre spese | €10.84m |
| Utili | -€37.52m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Sep 24, 2026
| Utile per azione (EPS) | -0.14 |
| Margine lordo | -370.12% |
| Margine di profitto netto | -520.44% |
| Rapporto debito/patrimonio netto | 1.7% |
Come si è comportato TNG nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 15:38 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Transgene SA è coperta da 5 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |